From: Next-generation sequencing in liquid biopsy: cancer screening and early detection
Company | Product/study | Usage/aim | Reference |
---|---|---|---|
Grail | The SUMMIT Study | Evaluating a blood test designed to detect multiple types of cancer, including lung cancer | [35] |
Guardant 360 | Lunar-2 | Early cancer detection among higher-risk asymptomatic individuals | [36] |
Freenome | Screening test | Using AI-based algorithm for early detection of colorectal cancer and precancerous lesions known as advanced adenomas | [37] |
Biocept | Target Selectorâ„¢ ctDNA EGFR Kit | EGFR mutation detection | [38] |
Inivata | InVisionSeqâ„¢ and InVisionFirstâ„¢- Lung | Around 40 biomarkers (including mutations, CNV, SNV, fusions, indels) panel for advanced cancers molecular profiling, monitoring, and diagnosis | [39] |
Cynvenio | The LiquidBiopsy® Platform | NGS-based techniques to detect mutations in as few as 1 target cell per mL/blood | [40] |
CellMaxLife | FirstSightCRCâ„¢ | Using circulating tumor cells for colorectal cancer, adenomas, and colorectal cancer screening and profiling | [41] |
Exosomedx | Exosome-based biomarker tests* | Diagnosing non-small cell lung cancer and prostate cancer | [42] |
Biodesix | GeneStrat® test | Providing blood-based mutation results of EGFR, ALK, ROS1, RET, BRAF, and KRAS for cancer diagnosis | [43] |
Personal Genome Diagnostics | PlasmaSELECTâ„¢ -R 64 | Cancer diagnosis using NGS with 64 Genes panel | [44] |